Fraunhofer   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Munich Germany (1949)

Organization Overview

First Clinical Trial
2008
NCT00766415
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Clinical Airway Research Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany | Fraunhofer Center for Manufacturing Innovation | Fraunhofer, Center for Molecular Biotechnology | Fraunhofer Gesellschaft | Fraunhofer-Gesellschaft | FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. | Fraunhofer IME | Fraunhofer institute | Fraunhofer Institute for Molecular Biology and Applied Ecology | Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany | Fraunhofer-Institute of Toxicology and Experimental Medicine | Fraunhofer Institut für Arbeitswirtschaft und Organisation | Fraunhofer ITEM | Fraunhofer ITEM Hannover, Germany | Fraunhofer ITEM in Hannover, Germany | Fraunhofer ITMP | Fraunhofer Portugal AICOS

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Conglobata (Phase 2)

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Anthrax (Phase 1)

Arthritis (Phase 4)

Arthritis, Psoriatic (Phase 3)

Asthma (Phase 2)

Deficiency Diseases (Phase 3)

Influenza in Birds (Phase 1)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 4)

Malaria (Phase 1)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Rheumatic Fever (Phase 4)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 31
  • # of Trial APIs: 34